Companies › EyePoint Pharmaceuticals
1 active drug program in 4 registered trials: 4 Phase 3; Ophthalmology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EYP-1901 VEGF inhibitor | – | Phase 3 | Wet Age Related Macular Degeneration; Diabetic Macular Edema | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06668064 | EYP-1901 | Phase 3 | Wet Age Related Macular Degeneration | Ophthalmology | Aug 2027 |
| NCT07449936 | EYP-1901 | Phase 3 | Diabetic Macular Edema | Ophthalmology | Oct 2027 |
| NCT06683742 | EYP-1901 | Phase 3 | Wet Age Related Macular Degeneration | Ophthalmology | Oct 2027 |
| NCT07449923 | EYP-1901 | Phase 3 | Diabetic Macular Edema | Ophthalmology | Oct 2027 |
Cash and short-term investments of $180m on 2026-06-30; operating cash outflow about $290m a year; runway about 8 months at that burn, to Feb 2027; 0 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Kodiak Sciences SpyGlass Pharma AiViva BioPharma Santen Pharmaceutical Adverum Biotechnologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.